Literature DB >> 12509133

Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model.

Urs Christen1, Matthias G von Herrath.   

Abstract

Autoimmunity is thought to emerge as a consequence of genetic predispositions and environmental tiggering factors. Often the etiology and the mechanisms involved in the autoaggressive destruction of self-components are rather complex and in many cases poorly understood. Chemokines and cytokines are central mediators of inflammatory processes that are involved in initiation and progression of autoimmunity. Many animal models for human autoimmune diseases use transgenic technology to express chemokines and/or cytokines in an organ or tissue specific manner. However, most of these model systems express the transgene irreversibly without considering the time of expression as a very important parameter. Here, we review experiences that were made from using a tetracycline-inducible promotor system (tTA-system) to express TNFalpha at various times during an ongoing autoimmune process, such as the destruction of pancreatic beta-cells in a mouse model for human type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12509133     DOI: 10.1023/a:1021144209209

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  29 in total

1.  Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances.

Authors:  U Baron; H Bujard
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM.

Authors:  M von Herrath; A Holz
Journal:  J Autoimmun       Date:  1997-06       Impact factor: 7.094

4.  Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice.

Authors:  Z Zhu; B Ma; R J Homer; T Zheng; J A Elias
Journal:  J Biol Chem       Date:  2001-04-30       Impact factor: 5.157

5.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

6.  Doxycycline control of prion protein transgene expression modulates prion disease in mice.

Authors:  P Tremblay; Z Meiner; M Galou; C Heinrich; C Petromilli; T Lisse; J Cayetano; M Torchia; W Mobley; H Bujard; S J DeArmond; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

7.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

Authors:  P A Furth; L St Onge; H Böger; P Gruss; M Gossen; A Kistner; H Bujard; L Hennighausen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA.

Authors:  S W Lee; A P Tsou; H Chan; J Thomas; K Petrie; E M Eugui; A C Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice.

Authors:  S Guerder; D E Picarella; P S Linsley; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model.

Authors:  M G von Herrath; J Dockter; M B Oldstone
Journal:  Immunity       Date:  1994-06       Impact factor: 31.745

View more
  4 in total

1.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

2.  In Vitro Effects of Some Botanicals with Anti-Inflammatory and Antitoxic Activity.

Authors:  Gianandrea Guidetti; Alessandro Di Cerbo; Angela Giovazzino; Valentina Rubino; Anna Teresa Palatucci; Sara Centenaro; Elena Fraccaroli; Laura Cortese; Maria Grazia Bonomo; Giuseppina Ruggiero; Sergio Canello; Giuseppe Terrazzano
Journal:  J Immunol Res       Date:  2016-08-15       Impact factor: 4.818

3.  Ins1(Cre) knock-in mice for beta cell-specific gene recombination.

Authors:  Bernard Thorens; David Tarussio; Miguel Angel Maestro; Meritxell Rovira; Eija Heikkilä; Jorge Ferrer
Journal:  Diabetologia       Date:  2014-12-11       Impact factor: 10.122

4.  Toxicological Implications and Inflammatory Response in Human Lymphocytes Challenged with Oxytetracycline.

Authors:  A Di Cerbo; A T Palatucci; V Rubino; S Centenaro; A Giovazzino; E Fraccaroli; L Cortese; G Ruggiero; G Guidetti; S Canello; G Terrazzano
Journal:  J Biochem Mol Toxicol       Date:  2015-11-05       Impact factor: 3.642

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.